In May 2018, we launched a prospective randomized phase II trial PSMA-PET guided intensification of radiotherapy studying the potential impact of PSMA PET/CT guided radiotherapy on outcomes of men deemed at high risk of harbouring undetected metastatic disease (NCT03525288). This evidence concerns the gene FOLH1 and metastatic neoplasm.